X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
APR-1051 is a next-generation WEE1 kinase inhibitor, which is being evaluated for the treatment of patients with cyclin E overexpressing breast and ovarian cancers.
Lead Product(s): APR-1051
Therapeutic Area: Oncology Product Name: APR-1051
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Aprea intends to use the net proceeds to fund clinical development of APR-1051, the Company’s oral, small molecule, WEE1 inhibitor product candidate which recently received IND clearance.
Lead Product(s): APR-1051
Therapeutic Area: Oncology Product Name: APR-1051
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Maxim Group LLC
Deal Size: $34.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 11, 2024
Details:
APR-1051 is a next generation, oral WEE1 Kinase inhibitor. It's IND-application is submitted after preclinical studies for the treatment of cancers including ovarian cancer.
Lead Product(s): APR-1051
Therapeutic Area: Oncology Product Name: APR-1051
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
ATRN-1051 is an orally bioavailable small molecule inhibitor of WEE1 that is highly potent and selective, which is investigated for treatment of ovarian cancer.
Lead Product(s): ATRN-1051
Therapeutic Area: Oncology Product Name: ATRN-1051
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
The net proceeds received from the public offering will enable the Company to continue developing its clinical asset, ATRN-119, its pre-clinical asset ATRN-W1051 and for general corporate purposes.
Lead Product(s): ATRN-119
Therapeutic Area: Oncology Product Name: ATRN-119
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Maxim Group LLC
Deal Size: $5.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 27, 2023
Details:
The net proceeds received from the public offering will enable the Company to continue developing its clinical asset, ATRN-119, its pre-clinical asset ATRN-W1051 and for general corporate purposes.
Lead Product(s): ATRN-119
Therapeutic Area: Oncology Product Name: ATRN-119
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Maxim Group LLC
Deal Size: $5.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 22, 2023
Details:
The grant will support an evaluation of the in vivo and in vitro activity and tolerability of ATRN-119 and ATRN-W1051 using a library of cell lines and patient-derived xenograft models of HGSOC that express varying levels of CCNE1.
Lead Product(s): ATRN-119
Therapeutic Area: Oncology Product Name: ATRN-119
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: $1.9 million Upfront Cash: Undisclosed
Deal Type: Funding February 15, 2023
Details:
ATRN-119 is an ATR inhibitor for the treatment of cancers with DDR mutations. It has demonstrated potent anti-proliferative activity against a variety of cancer cell lines, inhibited tumor growth in genetically defined ovarian, colon, pancreatic etc.
Lead Product(s): ATRN-119
Therapeutic Area: Oncology Product Name: ATRN-119
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
ATRN-W1051 is designed to be a potent and selective WEE1 inhibitor with a differentiated structure and potentially preferable pharmacokinetic properties.
Lead Product(s): ATRN-W1051
Therapeutic Area: Oncology Product Name: ATRN-W1051
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2022
Details:
Company’s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumorshas not yet been approved by the USFDA or any regulatory authority.
Lead Product(s): Eprenetapopt,Azacitidine
Therapeutic Area: Oncology Product Name: APR-246
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
